Johnson & Johnson (TSX:JNJ) Dividend-Payout-to-FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TSX:JNJ Johnson & Johnson TSX:JNJ
87 GF Score
Price C$34.46
GF Value C$24.98
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Johnson & Johnson Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.

TSX:JNJ
87GF Score
Johnson & Johnson TSX:JNJ
Dividend-Payout-to-FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Johnson & Johnson (TSX:JNJ) Overvalued in 2026?

Based on GuruFocus' analysis, Johnson & Johnson stock appears to be overvalued. The current stock price of C$34.46 is trading 38% above its estimated GF Value™ of C$24.98. GuruFocus considers Johnson & Johnson to be Significantly Overvalued.

Key valuation signals for TSX:JNJ:

  • Dividend-Payout-to-FFO:
  • GF Value™: C$24.98 vs. price of C$34.46 (38% above fair value)
  • GF Score™: 87/100 with 7 warning signs

No single metric tells the full story. See the TSX:JNJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Johnson & Johnson Business Description

Address One Johnson & Johnson Plaza, New Brunswick, NJ, USA, 08933
Johnson & Johnson, incorporated in New Jersey in 1887, is a holding company focused on products related to human health and well-being, with operating companies conducting business in virtually all countries and approximately 138,200 employees. It is organized into two segments. Innovative Medicine focuses on oncology (Darzalex, Carvykti, Erleada, Rybrevant), immunology (Stelara, Tremfya, Simponi), neuroscience (Spravato, Caplyta, Invega franchise), pulmonary hypertension (Opsumit, Uptravi), infectious diseases, and cardiovascular medicines, distributed to retailers, wholesalers, hospitals, and health professionals. MedTech develops and manufactures products used in cardiovascular intervention (including Abiomed heart pumps and Shockwave intravascular lithotripsy), electrophysiology, orthopaedics, surgery, and vision care, serving physicians, hospitals, and health systems across acute and elective procedures worldwide.
87GF Score

Get the complete analysis for TSX:JNJ

Dividend-Payout-to-FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$34.46
Price
C$24.98
GF Value